HOME
login
history
all enzymes
BRENDA home
History
Enzyme Nomenclature
Information on EC 1.14.15.4 - steroid 11beta-monooxygenase
for references in articles please use BRENDA:EC1.14.15.4
Word Map on EC 1.14.15.4
- 1.14.15.4
- hypertension
- cortisol
-
adrenocortical
-
steroidogenic
- corticosterone
- hyperplasia
- angiotensin
-
glucocorticoid
-
mineralocorticoid
-
steroidogenesis
- zona
- glomerulosa
- 21-hydroxylase
- 11-deoxycortisol
- renin
- adenoma
- metyrapone
- deoxycorticosterone
- fasciculata
- 11-deoxycorticosterone
- pregnenolone
- angiotensinogen
- androstenedione
-
beta-hydroxysteroid
- p450scc
- 17-hydroxyprogesterone
-
cushing
-
virilization
-
beta-hydroxylation
-
adrenodoxin
- spironolactone
- 18-hydroxycorticosterone
- cyp21a2
- 17alpha-hydroxylase
- eplerenone
- etomidate
- hirsutism
-
acth-stimulated
- hsd3b2
- 11-ketotestosterone
- hypokalemia
- pseudohermaphroditism
-
salt-wasting
-
liddle
-
low-renin
- drug development
- cyp19a1a
- trilostane
- atp1a1
- analysis
- medicine
- 11beta-hsd2
-
extra-adrenal
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
The enzyme appears in viruses and cellular organisms
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
EC NUMBER 
COMMENTARY 
1.14.15.4
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
RECOMMENDED NAME
GeneOntology No.
steroid 11beta-monooxygenase
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
both hydroxylation activities seem to occur in a single enzyme
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
both hydroxylation activities seem to occur in a single enzyme
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
both hydroxylation activities seem to occur in a single enzyme; heme protein of so-called P-450 family
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
P-45011beta responsible for two hydroxylase reactions
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
2 step reduction: reduction of P-450 with non-specific donor and reduction which is specifically dependent on reduced iron-sulfur protein
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
11beta-/18-hydroxylation and aldosterone synthesis are catalyzed by 2 distinct forms of cytochrome P-45011beta
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
11beta-/18-hydroxylation and aldosterone synthesis are catalyzed by 2 distinct forms of cytochrome P-45011beta
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
cytochrome P45011beta is implicated in mineralocorticoid, synthesized and secreted from zona glomerulosa, as well as glucocorticoid, secreted primarily in zonae fasciculate and reticularis, biosynthesis with multiple catalytic activities, 11beta-/18-/19-hydroxylase and 18-/19-hydroxysteroid oxidase activities
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
ferric cytochrome P-45011beta-deoxycorticosterone complex classified as a pentacoordinated species, H2O molecule binds ferric heme iron
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
for synthesis of aldosterone 3 molecules P450 must be reduced or one molecule must be reduced 3 times
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
superfamily of heme-containing enzyme, 11-/18-/19-hydroxylations of 11-deoxycorticosterone, 11-deoxycortisol and androstenedione
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
single enzyme, 11beta-/18-hydroxylation and aldosterone synthetic activities
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
one bifunctional cytochrome P-450, 11beta-/14alpha-hydroxylation
-
a steroid + 2 reduced adrenodoxin + O2 + 2 H+ = an 11beta-hydroxysteroid + 2 oxidized adrenodoxin + H2O
A heme-thiolate protein (P-450). Also hydroxylates steroids at the 18-position, and converts 18-hydroxycorticosterone into aldosterone. Formerly EC 1.14.1.6 and 1.99.1.7
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydroxylation
-
-
-
-
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
steroid,reduced-adrenal-ferredoxin:oxygen oxidoreductase (11beta-hydroxylating)
A heme-thiolate protein (P-450). Also hydroxylates steroids at the 18-position, and converts 18-hydroxycorticosterone into aldosterone.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9029-66-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
sole protogynous freshwater fish found that exhibits an adult sex change from functional females to males
UniProt
-
285389, 285390, 285391, 285393, 285394, 285395, 285396, 285398, 285399, 285400, 285402, 285403, 285404, 285405
-
-
-
285407, 659682, 659683, 672590, 673348, 673925, 675052, 675053, 675054, 675295, 675684, 686170, 686714, 688587, 688588, 690171, 690201, 711420, 711434, 712572, 712695, 712715, 724701, 726012, 726468
-
-
male Wistar rats with heart failure induced by coronary artery ligation and sham-operated controls, stroke-prone spontaneously hypertensive rats and Wistar Kyoto rats as controls, cyp1a1Ren-2 transgenic rats and Fischer controls, and adult Sprague-Dawley rats
-
-
male, Zur:SIV low sodium, high potassium or high sodium, low potassium treated for stimulation or supprssion, respectively
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
-
although the active site pocket is lined by identical residues between CYP11B isoforms, most of the divergent residues that confer additional 18-oxidase activity of aldosterone synthase are located in the I-helix, vicinity of the O2 activation path and loops around the H-helix, affecting an egress channel closure required for retaining intermediates in the active site; although the active site pocket is lined by identical residues between CYP11B isoforms, most of the divergent residues that confer additional 18-oxidase activity of aldosterone synthase are located in the I-helix, vicinity of the O2 activation path and loops around the H-helix, affecting an egress channel closure required for retaining intermediates in the active site
malfunction
metabolism
physiological function
additional information
malfunction
-
overproduction of aldosterone in the adrenal gland can lead to hypertension, a major cause of heart disease and stroke
malfunction
-
familial hyperaldosteronism type I is caused by the unequal recombination between the 11beta-hydroxylase CYP11B1 and aldosterone synthase CYP11B2 genes, resulting in the generation of a CYP11B1/B2 chimeric gene and abnormal adrenal aldosterone production, which leads to severe hypertension and an elevated frequency of stroke at a young age
metabolism
-
CYP11B1 is a key enzyme in the biosynthesis of cortisol. CYP11B2 catalyzes the last three steps of aldosterone biosynthesis
metabolism
-
aldosterone synthase, CYP11B2, is the key enzyme of mineralocorticoid biosynthesis and its malfunction is involved in hyperaldosteronism, congestive heart failure, and myocardial fibrosis
metabolism
-
very-low-density lipoprotein mediates transcriptional upregulation of aldosterone synthase in human adrenocortical cells through multiple signaling pathways, e.g. partially through scavenger receptor class B type I. Aldosterone, apart from its role in fluid and electrolyte homeostasis, is implicated in insulin resistance and myocardial fibrosis. Impact of VLDL as a potential risk factor for aldosterone-mediated cardiovascular injury in diabetes mellitus, intracellular mechanism, overview
metabolism
-
human aldosterone synthase is responsible for the biosynthesis of aldosterone from 11-deoxycorticosterone in a sequential three-step reaction with two intermediates, corticosterone and 18-hydroxycorticosterone
physiological function
-
steroid 11beta-hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively
physiological function
-
aldosterone synthase, CYP11B2, is the sole enzyme responsible for the production of aldosterone in humans
physiological function
-
aldosterone synthase regulates blood volume by synthesizing the mineralocorticoid aldosterone. Subcellular mechanisms of enzyme localization relate to production of aldosterone and reveal a rapid, promoter-independent regulation of aldosterone production
physiological function
-
progesterone might regulate the 11beta-hydroxylase CYP11B1 and aldosterone synthase CYP11B2 enzymatic activities and contribute to the decay of aldosterone synthase activity in CYP11B1/B2 chimeric gene-positive patients. This regulatory mechanism of progesterone action might be involved in protecting pregnant women with FH-1 against hypertension
additional information
-
steroid 11beta-hydroxylase, CYP11B1, deficiency, i.e. 11OHD, is the second most common form of congenital adrenal hyperplasia. Cases of nonclassic 11OHD are rare compared with the incidence of nonclassic 21-hydroxylase deficiency, genotypes and phenotypes, overview
additional information
-
homology modeling and molecular docking of CYP11B2, overview
additional information
-
a hydrophobic cavity with specific features is associated with corticosteroid recognition, substrate binding mode, overview; a hydrophobic cavity with specific features is associated with corticosteroid recognition, substrate binding mode, overview
additional information
-
N-terminal 26 amino acids of the enzyme target cargo protein DHFR to the mitochondria
additional information
-
molecular modelling of CYP11B1 and CYP11B1/B2 chimeric proteins and steroids docking, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
11-deoxy-cortisol + reduced ferredoxin + O2
cortisol + ferredoxin + H2O
-
-
-
-
?
11-deoxycorticosterone + adrenal ferredoxin + H2O
corticosterone + reduced adrenal ferredoxin + O2
-
-
-
-
?
11-deoxycorticosterone + NADPH + O2
18-hydroxycorticosterone + NADP+ + H2O
-
-
-
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
?
-
-
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
11-deoxycortisol + adrenal ferredoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
-
-
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
14alpha-hydroxy-11-deoxycortisol + oxidized adrenal ferredoxin + H2O
-
11alpha-hydroxylase activity
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
11-deoxycortisol + reduced adrenodoxin + O2
cortisol + oxidized adrenodoxin + H2O
-
-
-
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
17alpha,21-dihydroxy-pregn-4-ene-3,20-dione + reduced adrenal ferredoxin + O2
11beta,17alpha,21-trihydroxy-pregn-4-ene-3,20-dione + oxidized adrenal ferredoxin + H2O
-
i.e. Reichstein's compound, inducer
hydrocortisone, 60%, 11beta hydroxylation
?
17alpha,21-dihydroxy-pregn-4-ene-3,20-dione + reduced adrenal ferredoxin + O2
14alpha,17alpha,21-trihydroxy-pregn-4-ene-3,20-dione + oxidized adrenal ferredoxin + H2O
-
i.e. Reichstein's compound, inducer
25%, 14alpha hydroxylation
?
18-hydroxy-corticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenodoxin + O2
aldosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
19-hydroxy-11-deoxycorticosterone + reduced adrenal ferredoxin + O2
19-oxo-11-deoxycorticosterone + oxidized adrenal ferredoxin + H2O
-
-
-
?
4-androstene-3,17-dione + reduced adrenal ferredoxin + O2
11beta-hydroxy-4-androstene-3,17-dione + oxidized adrenal ferredoxin + H2O
-
i.e. testosterone, 11beta-/19-hydroxylase activity, good sustrate
-
?
4-androstene-3,17-dione + reduced adrenal ferredoxin + O2
19-hydroxy-4-androstene-3,17-dione + oxidized adrenal ferredoxin + H2O
-
i.e. testosterone, 11beta-/19-hydroxylase activity, good sustrate
-
?
4-pregnen-21-ol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,21-diol-3,20-dione + oxidized adrenal ferredoxin + H2O
4-pregnene-17,21-diol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,17,21-triol-3,20-dione + oxidized adrenal ferredoxin + H2O
a steroid + reduced adrenodoxin + O2
an 11beta-hydroxysteroid + oxidized adrenodoxin + H2O
-
-
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + H2O
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxy-11-deoxycorticosterone + oxidized adrenal ferredoxin + H2O
-
addition of adrenodoxin and adrenodoxin reductase
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxy-corticosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
corticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
cortisol + reduced adrenal ferredoxin + O2
cortisone + oxidized adrenal ferredoxin + H2O
-
-
-
?
metyrapone + ?
metyrapol + ?
-
plasma, product-stereoselective reductive metabolism
enantiomers
r
progesterone + reduced adrenodoxin + O2
11beta-hydroxyprogesterone + oxidized adrenodoxin + H2O
testosterone + reduced adrenal ferredoxin + O2
11beta-hydroxytestosterone + oxidized adrenal ferredoxin + H2O
-
at low rate
-
-
?
testosterone + reduced adrenodoxin + O2
11-hydroxytestosterone + oxidized adrenodoxin + H2O
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
-
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
11beta-hydroxylase and 18-hydroxylase activities, after replacement of Tween 20 by phosphatidylcholine catalytic activity for aldosterone activity is exhibited, form 1 higher active in aldosterone and 18-hydroxycorticosterone production and less active in the production of corticosterone and 18-hydroxydeoxycorticosterone from deoxycorticosterone as form 2
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
11beta-/18-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
3 steps in glomerulosa catalysed by one enzyme, 11beta-hydroxylation to corticosterone, 18-hydroxylation to 18-hydroxycorticosterone and aldehyde synthesis to aldosterone
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
3 step 11beta-/18-hydroxylation to aldosterone
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
49 kDa protein, exclusively in zona glomerulosa, 11beta -hydroxylation, as well as 18-hydroxylation and 18-hydroxydehydrogenation of corticosterone with 18-hydroxydeoxycorticosterone and 18-hydroxycorticosterone as intermediates
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
49 kDa protein, exclusively in zona glomerulosa, 11beta -hydroxylation, as well as 18-hydroxylation and 18-hydroxydehydrogenation of corticosterone with 18-hydroxydeoxycorticosterone and 18-hydroxycorticosterone as intermediates
product of 49 kDa protein
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
51 kDa protein, zona fasciculata and glomerulosa, high sodium and low potassium, 11beta-/18-hydroxylation
product of 49 kDa protein
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
by 49.5 kDa protein from capsular portion, 11beta-/18-hydroxylation by 51.5 kDa protein
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + 2 H+ + 2 O2
aldosterone + oxidized adrenal ferredoxin + 2 H2O
-
supported by adrenodoxin and adrenodoxin reductase, 3 step-hydroxylation with corticosterone and 18-hydroxycorticosterone as intermediates, 11beta-/18-hydroxylase
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
containing adrenal ferredoxin, adrenal ferredoxin reductase and P-45011beta, highly active hydroxylation, 11beta-/18-hydroxylase activity
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
by 49.5 kDa protein from capsular portion, 11beta-/18-hydroxylation by 51.5 kDa protein
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
18-/11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
containing adrenal ferredoxin, adrenal ferredoxin reductase and P-45011beta, highly active hydroxylation, 11beta-/18-hydroxylase activity
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
addition of adrenodoxin and adrenodoxin reductase
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
addition of adrenodoxin and adrenodoxin reductase
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
by 49.5 kDa protein from capsular portion, 11beta-/18-hydroxylation by 51.5 kDa protein
51.5 kDa protein
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
18-/11beta-hydroxylation
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
adrenal
-
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
-
i.e. 21-hydroxyprogesterone
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
-
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
CYP11B1
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
CYP11B1
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
deficiency of steroid 11-hydroxylase CYP11B1 due to mutations in the CYP11B1 gene causes congenital adrenal hyperplasia, a group of autosomal recessive disorders, overview
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
cytochrome P-45011beta-linked monoxygenase
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylase activity
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
-
the product is an important intermediate for many anti-inflammatory drugs
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
assay optimization
-
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
-
the product is an important intermediate for many anti-inflammatory drugs
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
assay optimization
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
-
-
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
-
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
-
CYP11B2
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
-
18-hydroxylation
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
-
18-hydroxylation, aldosterone production exclusively in the zona glomerulosa
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
-
-
-
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
aldosterone is one of the main effectors of the reninangiotensinaldosterone system, RAAS, regulating salt and water homeostasis and thereby also blood pressure
-
-
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
-
-
-
?
4-pregnen-21-ol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,21-diol-3,20-dione + oxidized adrenal ferredoxin + H2O
-
11-deoxycorticosterone, fumarate required in mitochondria treated with hypotonic solutions of electrolytes
-
-
-
4-pregnen-21-ol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,21-diol-3,20-dione + oxidized adrenal ferredoxin + H2O
-
11-hydroxylation
-
?
4-pregnen-21-ol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,21-diol-3,20-dione + oxidized adrenal ferredoxin + H2O
-
11-hydroxylation
-
?
4-pregnene-17,21-diol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,17,21-triol-3,20-dione + oxidized adrenal ferredoxin + H2O
-
11-hydroxylation
-
?
4-pregnene-17,21-diol-3,20-dione + reduced adrenal ferredoxin + O2
4-pregnene-11,17,21-triol-3,20-dione + oxidized adrenal ferredoxin + H2O
-
11-hydroxylation
-
?
androstendione + reduced adrenodoxin + O2
? + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B1
-
-
?
androstendione + reduced adrenodoxin + O2
? + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B2
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + H2O
-
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + H2O
-
-
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
addition of adrenodoxin and adrenodoxin reductase
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation
-
?
corticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation
-
?
corticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxycorticosterone as intermediate of 11beta-hydroxylation
-
?
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + H2O
-
-
-
-
?
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + H2O
-
in the adrenal zona fasciculata
-
-
?
progesterone + reduced adrenodoxin + O2
11beta-hydroxyprogesterone + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B1
-
-
?
progesterone + reduced adrenodoxin + O2
11beta-hydroxyprogesterone + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B2
-
-
?
testosterone + reduced adrenodoxin + O2
11-hydroxytestosterone + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B1
-
-
?
testosterone + reduced adrenodoxin + O2
11-hydroxytestosterone + oxidized adrenodoxin + H2O
-
low activity with isozyme CYP11B2
-
-
?
additional information
?
-
-
the enzyme is involved in sex differentiation in the protandrous anemonefish, overview
-
-
-
additional information
?
-
-
corticosterone generally believed to be preferred substrate for 18-hydroxylase
-
-
-
additional information
?
-
the enzyme is involved in gonadal transformation in the zebrafish, enzyme expression regulation, overview
-
-
-
additional information
?
-
-
the enzyme is involved in gonadal transformation in the zebrafish, enzyme expression regulation, overview
-
-
-
additional information
?
-
-
a key mitochondrial enzyme for the production of 11-oxygenated androgens, which have been shown to be potent masculinising steroids in several fish species, it plays a role in testicular development
-
-
-
additional information
?
-
-
-344T/C polymorphism is associated with a clinically relevant phenotype for diabetic nephropathy such as hypertension
-
-
-
additional information
?
-
-
CYP11B2-CYP11B1 haplotypes associate with decreased 11beta-hydroxylase activity, overview
-
-
-
additional information
?
-
-
effects of enzyme inhibition of steroid biosynthesis and mineralcorticoid formation, overview
-
-
-
additional information
?
-
-
enzyme deficiency is a cause for congenital adrenal hyperplasia, overview
-
-
-
additional information
?
-
-
genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor 11-deoxycortisol urinary metabolite excretion, overview
-
-
-
additional information
?
-
-
non-classical enzyme deficiency causes mild androgen excess, hirsutism, precocious adrenarche and accelerated growth in children, missense mutations are responsible for non-classical adrenal hyperplasia in children, overview
-
-
-
additional information
?
-
-
variation of 344 C/T and intron 2 in the CYP11B2 gene, encoding aldosterone synthase, is associated with CYP11B1 deficiency due to variations of gene CYP11B1 at positions 1889 and 1859 and disequiliibrium with CYP11B2, overview
-
-
-
additional information
?
-
-
11-beta-hydroxylase deficiency, i.e. 11betaOHD is caused by CYP11B1 gene defects and leads to congenital adrenal hyperplasia associated with hypertension, overview
-
-
-
additional information
?
-
-
11beta-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia after 21-hydroxylase deficiency, overview
-
-
-
additional information
?
-
-
congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency is a genetic disorder of steroidogenesis, transmitted as an autosomal recessive trait. It is associated with low renin hypertension, hypokalemia, hyperandrogenemia and genital ambiguity in affected females, overview
-
-
-
additional information
?
-
-
deficiency of 11beta-hydroxylase results in decreased synthesis of cortisol and glucocorticoids, and thus causes weakened depressive feedback ofACTH and increased synthesis of ACTH in pituitary, which leads to production of more cortisol precursor in zona fasciculata, enzyme regulation, overview
-
-
-
additional information
?
-
-
enzyme deficiency leads to hypokalemia and further, when under-treated, to rhabdomyolysis, overview
-
-
-
additional information
?
-
-
the enzyme is regulated by adrenocorticotrophic hormone, ACTH
-
-
-
additional information
?
-
-
the polymorphism genotype of gene CYP11B2, encoding aldosterone synthase, affects the activity of the 11beta-hydroxylase, encoded by gene CYP11B1, overview
-
-
-
additional information
?
-
-
the recombinant enzyme is capable of hydroxylating its substrates at position 11-beta
-
-
-
additional information
?
-
enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
-
-
-
additional information
?
-
enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
-
-
-
additional information
?
-
-
CYP11B2 hydroxylates 18-hydroxycorticosterone
-
-
-
additional information
?
-
-
steroid 11beta-hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively
-
-
-
additional information
?
-
-
bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
-
-
-
additional information
?
-
-
N-terminally unprocessed enzyme has 2fold more activity than the mature physiological enzyme
-
-
-
additional information
?
-
-
aldosterone synthase shows high 11beta-hydroxylase activity toward both gluco- and mineralocorticoid formation, and additional 18-oxidase activity, substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No oxidation activity of CYP11B2 with 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and poor activity with cortisol
-
-
-
additional information
?
-
-
substrate specificties of isozymes CYP11B2 and CYP11B1, overview. No or poor activity of CYP11B1 with cortisol, 18-hydroxycorticosterone, 11-dehydrocorticosterone, 21-hydroxypregnenolone, and 11beta-hydroxyprogesterone
-
-
-
additional information
?
-
-
the concomitant down-regulation of P450arom and up-regulation of P45011beta are of pivotal importance to the sex change
-
-
-
additional information
?
-
the concomitant down-regulation of P450arom and up-regulation of P45011beta are of pivotal importance to the sex change
-
-
-
additional information
?
-
-
prolactin regulatory element-binding (PREB) protein. It regulates the transcription of the CYP11B1 gene via cAMP. PREB can function as a transcriptional regulator of the CYP11B1 promoter. PREB binds to the CYP11B1 promoter, and in cells expressing PREB, it increases CYP11B1 expression. Knockdown of PREB expression attenuated the effects of cAMP on CYP11B1 expression. CYP11B1 promoter activity is increased in the cells treated with the scrambled siRNA and cAMP, while the CYP11B1 promoter activity is markedly reduced in the cells treated with the PREB-specific siRNA. Enzyme is regulated by cAMP, which stimulates the expression of PREB. Knockdown of PREB expression attenuates the effects of cAMP on CYP11B1 expression
-
-
-
additional information
?
-
-
responsible for the last step of glucocorticoid biosynthesis in the adrenal cortices of many kinds of animals
-
-
-
additional information
?
-
-
androgen production of male animal is partially regulated by changes in abundance of enzyme mRNA
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
11-deoxy-cortisol + reduced ferredoxin + O2
cortisol + ferredoxin + H2O
-
-
-
-
?
11-deoxycorticosterone + reduced adrenal ferredoxin + O2
corticosterone + oxidized adrenal ferredoxin + H2O
-
11beta-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
11-deoxycorticosterone + reduced adrenodoxin + O2
corticosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
11-deoxycortisol + adrenal ferredoxin + H2O
cortisol + reduced adrenal ferredoxin + O2
-
-
-
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
18-hydroxy-corticosterone + reduced adrenal ferredoxin + O2
aldosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
18-hydroxycorticosterone + reduced adrenodoxin + O2
aldosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
11-deoxycorticosterone + adrenal ferredoxin + H2O
-
-
-
-
?
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxy-corticosterone + oxidized adrenal ferredoxin + H2O
-
18-hydroxylation, last 3 steps of pathway for aldosterone biosynthesis
-
?
corticosterone + reduced adrenodoxin + O2
18-hydroxycorticosterone + oxidized adrenodoxin + H2O
-
-
-
-
?
cortisol + reduced adrenal ferredoxin + O2
11-deoxycortisol + adrenal ferredoxin + H2O
-
in the adrenal zona fasciculata
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
-
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
P15538
-
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
CYP11B1
-
-
?
11-deoxycortisol + reduced adrenal ferredoxin + O2
cortisol + adrenal ferredoxin + H2O
-
deficiency of steroid 11-hydroxylase CYP11B1 due to mutations in the CYP11B1 gene causes congenital adrenal hyperplasia, a group of autosomal recessive disorders, overview
-
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
-
the product is an important intermediate for many anti-inflammatory drugs
-
?
16,17alpha-epoxyprogesterone + reduced adrenal ferredoxin + O2
11beta-hydroxy-16,17alpha-epoxyprogesterone + adrenal ferredoxin + H2O
-
-
the product is an important intermediate for many anti-inflammatory drugs
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
-
-
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
P15538
-
-
-
?
18-hydroxycorticosterone + reduced adrenal ferredoxin + O2
aldosterone + adrenal ferredoxin + H2O
-
CYP11B2
-
-
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
aldosterone is one of the main effectors of the reninangiotensinaldosterone system, RAAS, regulating salt and water homeostasis and thereby also blood pressure
-
-
?
18-hydroxycorticosterone + reduced ferredoxin + O2
aldosterone + ferredoxin + H2O
-
-
-
-
?
additional information
?
-
-
the enzyme is involved in sex differentiation in the protandrous anemonefish, overview
-
-
-
additional information
?
-
-
corticosterone generally believed to be preferred substrate for 18-hydroxylase
-
-
-
additional information
?
-
A1XRK1
the enzyme is involved in gonadal transformation in the zebrafish, enzyme expression regulation, overview
-
-
-
additional information
?
-
-
the enzyme is involved in gonadal transformation in the zebrafish, enzyme expression regulation, overview
-
-
-
additional information
?
-
-
a key mitochondrial enzyme for the production of 11-oxygenated androgens, which have been shown to be potent masculinising steroids in several fish species, it plays a role in testicular development
-
-
-
additional information
?
-
-
-344T/C polymorphism is associated with a clinically relevant phenotype for diabetic nephropathy such as hypertension
-
-
-
additional information
?
-
-
CYP11B2-CYP11B1 haplotypes associate with decreased 11beta-hydroxylase activity, overview
-
-
-
additional information
?
-
-
effects of enzyme inhibition of steroid biosynthesis and mineralcorticoid formation, overview
-
-
-
additional information
?
-
-
enzyme deficiency is a cause for congenital adrenal hyperplasia, overview
-
-
-
additional information
?
-
-
genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor 11-deoxycortisol urinary metabolite excretion, overview
-
-
-
additional information
?
-
-
non-classical enzyme deficiency causes mild androgen excess, hirsutism, precocious adrenarche and accelerated growth in children, missense mutations are responsible for non-classical adrenal hyperplasia in children, overview
-
-
-
additional information
?
-
-
variation of 344 C/T and intron 2 in the CYP11B2 gene, encoding aldosterone synthase, is associated with CYP11B1 deficiency due to variations of gene CYP11B1 at positions 1889 and 1859 and disequiliibrium with CYP11B2, overview
-
-
-
additional information
?
-
-
11-beta-hydroxylase deficiency, i.e. 11betaOHD is caused by CYP11B1 gene defects and leads to congenital adrenal hyperplasia associated with hypertension, overview
-
-
-
additional information
?
-
-
11beta-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia after 21-hydroxylase deficiency, overview
-
-
-
additional information
?
-
-
congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency is a genetic disorder of steroidogenesis, transmitted as an autosomal recessive trait. It is associated with low renin hypertension, hypokalemia, hyperandrogenemia and genital ambiguity in affected females, overview
-
-
-
additional information
?
-
-
deficiency of 11beta-hydroxylase results in decreased synthesis of cortisol and glucocorticoids, and thus causes weakened depressive feedback ofACTH and increased synthesis of ACTH in pituitary, which leads to production of more cortisol precursor in zona fasciculata, enzyme regulation, overview
-
-
-
additional information
?
-
-
enzyme deficiency leads to hypokalemia and further, when under-treated, to rhabdomyolysis, overview
-
-
-
additional information
?
-
-
the enzyme is regulated by adrenocorticotrophic hormone, ACTH
-
-
-
additional information
?
-
-
the polymorphism genotype of gene CYP11B2, encoding aldosterone synthase, affects the activity of the 11beta-hydroxylase, encoded by gene CYP11B1, overview
-
-
-
additional information
?
-
P15538
enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
-
-
-
additional information
?
-
P19099
enzyme is responsible for the final step of aldosterone synthesis. It requires electron transfer from the adrenodoxin/adrenodoxin reductase system to catalyze the production of aldosterone
-
-
-
additional information
?
-
-
CYP11B2 hydroxylates 18-hydroxycorticosterone
-
-
-
additional information
?
-
-
steroid 11beta-hydroxylase converts 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively
-
-
-
additional information
?
-
-
bifunctional enzyme catalyzing the biosynthesis of aldosterone by successive 11beta- and 18-hydroxylation followed by an 18-oxidation of 11-deoxycorticosterone
-
-
-
additional information
?
-
-
N-terminally unprocessed enzyme has 2fold more activity than the mature physiological enzyme
-
-
-
additional information
?
-
-
the concomitant down-regulation of P450arom and up-regulation of P45011beta are of pivotal importance to the sex change
-
-
-
additional information
?
-
Q2I128
the concomitant down-regulation of P450arom and up-regulation of P45011beta are of pivotal importance to the sex change
-
-
-
additional information
?
-
-
prolactin regulatory element-binding (PREB) protein. It regulates the transcription of the CYP11B1 gene via cAMP. PREB can function as a transcriptional regulator of the CYP11B1 promoter. PREB binds to the CYP11B1 promoter, and in cells expressing PREB, it increases CYP11B1 expression. Knockdown of PREB expression attenuated the effects of cAMP on CYP11B1 expression. CYP11B1 promoter activity is increased in the cells treated with the scrambled siRNA and cAMP, while the CYP11B1 promoter activity is markedly reduced in the cells treated with the PREB-specific siRNA. Enzyme is regulated by cAMP, which stimulates the expression of PREB. Knockdown of PREB expression attenuates the effects of cAMP on CYP11B1 expression
-
-
-
additional information
?
-
-
responsible for the last step of glucocorticoid biosynthesis in the adrenal cortices of many kinds of animals
-
-
-
additional information
?
-
-
androgen production of male animal is partially regulated by changes in abundance of enzyme mRNA
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
ascorbate
-
plus NADH very low conversion and no aldosterone production, in synergism with NADH, malate and NADP+ increase of aldosterone synthetase activity in zona glomerulosa, not zona fasciculate
NADP+
-
plus malate supports all 4 conversions, increase of aldosterone synthetase activity
additional information
-
cofactor screening, overview, the enzyme is active with NADPH
-
NADPH
-
adrenodoxin and NADPH-linked adrenodoxin reductase; requirement during inactivation
NADPH
-
adrenodoxin and NADPH-linked adrenodoxin reductase
NADPH
-
adrenodoxin and adrenodoxin reductase required in cell line homogenates, in living cells in absence of cofactors
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Fe2+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1R)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
-
-
(1S)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
-
-
(5Z)-5-(1H-imidazol-5-ylmethylene)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
-
50% inhibition at 0.0069 mM, selective for CYP11B1
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
-
FAD286; FAD286, CYP11B2 inhibitor, inhibited CYP11B2 and CYP11B1 activities
1-(1H-inden-2-yl)-1H-imidazole
-
CYP11B2 IC50: 448 nM, no inhibition of CYP11B1, recombinant enzymes
1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
-
CYP11B1 IC50: 639 nM, CYP11B2 IC50: 334 nM, recombinant enzymes
1-(6-methoxy-3,4-dihydronaphthalen-2-yl)-1H-imidazole
-
CYP11B1 IC50: 763 nM, CYP11B2 IC50: 411 nM, recombinant enzymes
18-vinyldeoxycorticosterone
-
deoxycorticosterone analog, very strong and reversible inhibitor for deoxycorticosterone and corticosterone oxidation, 0.001 mM leads to decrease in corticosterone production with 30% of total activity after 1 min, 100fold more efficient than 18-vinylprogesterone for inhibition of 11beta-hydroxylation step, only 6fold of more inhibition of 18-hydroxylation step
2,3-dichloro-N-(pyridin-3-yl)benzamide
-
51% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B22
2,4,5-trifluoro-N-(pyridin-3-yl)benzamide
-
70% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B23
2-(4-chlorobenzyl)-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-(4-fluorobenzyl)-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-benzyl-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-fluoro-N-(pyridin-3-yl)benzamide
-
34% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B19
2-[(1R)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(3-methoxy-2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(cyclopropylmethyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(3-methyloxetan-3-yl)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(propan-2-yloxy)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
3,4-difluoro-N-(pyridin-3-yl)benzamide
-
83% inhibition of CYP11B2 at 0.5 mM, 6% inhibition of CYP11B20
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
-
CYP11B1 IC50: 2117 nM, CYP11B2 IC50: 30 nM, recombinant enzymes
3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
-
CYP11B1 IC50: 1268 nM, CYP11B2 IC50: 7 nM, recombinant enzymes
3-(3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B1 IC50: 1729 nM, CYP11B2 IC50: 7 nM, recombinant enzymes
3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B1 IC50: 503 nM, CYP11B2 IC50: 5 nM, recombinant enzymes
3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B1 IC50: 1615 nM, CYP11B2 IC50: 176 nM, recombinant enzymes
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B1 IC50: 1291 nM, CYP11B2 IC50: 13 nM, recombinant enzymes
3-(6-methoxy-1H-inden-2-yl)pyridine
-
competitive, CYP11B1 IC50: 5684 nM, CYP11B2 IC50: 4 nM, recombinant enzymes
3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
-
competitive, CYP11B1 IC50: 578 nM, CYP11B2 IC50: 2 nM, recombinant enzymes
3-(7-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B2 IC50: 45 nM, no inhibition of CYP11B1, recombinant enzymes
3-chloro-N-(pyridin-3-yl)benzamide
-
26% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B18
3-fluoro-N-(pyridin-3-yl)benzamide
-
47% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B17
3-[(Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine
-
50% inhibition at 0.087 mM
3-[(Z)-2-phenylvinyl]pyridine
-
CYP11B1 IC50: 288 nM, CYP11B2 IC50: 735 nM, no inhibition by the 3-[(E)-2-phenylvinyl]pyridine isomer, recombinant enzymes
3-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-2-methylpropan-1-ol
-
-
4-(2-methylpropyl)-2-(thiophen-2-ylmethyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
4-(2-methylpropyl)-2-[4-(trifluoromethoxy)benzyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
4-(2-methylpropyl)-2-[4-(trifluoromethyl)benzyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
-
-
4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
-
CYP11B1 IC50: 2529 nM, CYP11B2 IC50: 2834 nM, recombinant enzymes
4-bromo-N-(pyridin-3-yl)benzamide
-
64% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B9
4-chloro-N-(pyridin-3-yl)benzamide
-
88% inhibition of CYP11B2 at 0.5 mM, 5% inhibition of CYP11B8
4-cyano-N-(pyridin-3-yl)benzamide
-
81% inhibition of CYP11B2 at 0.5 mM, 9% inhibition of CYP11B15
4-fluoro-N-(pyridin-3-yl)benzamide
-
86% inhibition of CYP11B2 at 0.5 mM, 7% inhibition of CYP11B7
4-methoxy-N-(pyridin-3-yl)benzamide
-
19% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B10
4-methyl-N-(pyridin-3-yl)benzamide
-
25% inhibition of CYP11B2 at 0.5 mM, no% inhibition of CYP11B13
4-nitro-N-(pyridin-3-yl)benzamide
-
64% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B16
4-[(Z)-(5-fluoro-2,3-dihydro-1H-inden-1-ylidene)methyl]pyridine
-
50% inhibition at 0.034 mM, selective for CYP11B1
5-bromo-N-(pyridin-3-yl)pyridine-3-carboxamide
-
29% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B5
5-[(1E)-1-(5-fluoro-2,3-dihydro-1H-inden-1-ylidene)ethyl]isoquinoline
-
50% inhibition at 0.096 mM
5-[(E)-(5-fluoro-2,3-dihydro-1H-inden-1-ylidene)methyl]isoquinoline
-
50% inhibition at 0.058 mM, selective for CYP11B1
5-[(E)-(5-fluoro-2,3-dihydro-1H-inden-1-ylidene)methyl]pyrimidine
-
50% inhibition at 0.027 mM, very selective for CYP11B1
5-[(Z)-(5-fluoro-2,3-dihydro-1H-inden-1-ylidene)methyl]isoquinoline
-
50% inhibition at 0.026 mM, selective for CYP11B1
5-[(Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]-1H-imidazole
-
50% inhibition at 0.0061 mM
5-[(Z)-3,4-dihydronaphthalen-1(2H)-ylidenemethyl]-1H-imidazole
-
50% inhibition at 0.0033 mM
6,6-dimethyl-8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
6-(5,8-dihydroisoquinolin-4-yl)-3,4-dihydroquinolin-2(1H)-one
-
94% inhibition of CYP11B2 at 0.5 mM, 91% inhibition of CYP11B1
8-(2,3'-bipyridin-5-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-(5-ethoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-(5-fluoropyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-(5-hydroxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-(5-methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-(5-phenylpyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-one
-
-
8-[5-(2,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(2-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(2-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(3,4-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(3,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(3-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(3-hydroxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(3-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(4-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(4-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(propan-2-yloxy)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-(trifluoromethyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-[3-(trifluoromethoxy)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
8-[5-[3-(trifluoromethyl)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
-
-
9-(5-methoxypyridin-3-yl)-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
-
-
9-[6-(isoquinolin-4-yl)pyridin-3-yl]-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
-
-
clotrimazole
-
azole derivative, antimycotic drug, strong dose-dependent inhibition
diphosphatidyl glycerol
-
cardiolipin, dipalmitoyl phasphatidylcholine vesicles, 50% inhibition with 4-5 mol%, complete inhibition at 15 mol%
methyltrienolone
-
synthetic androgen, used as photoaffinity ligand and substrate analog, covalent binding, 0.1 mM inhibits cortisol synthesis, during photolabeling radioactivity incorporation via radioactive methyltrienolone is blocked by 11-deoxycorticosterone, so it binds to the conserved substrate binding region Trp428-Leu429-Asp430-Arg431 between beta3-sheet and the L-helix analysed by trypsin digest
metyrapol
-
11beta-hydroxylase inhibition, 40.8% by racemate, 38.1% by (+)-enantiomer and 33.8% by (-)-enantiomer, each 0.4 mM
miconazole
-
azole derivative, antimycotic drug, strong dose-dependent inhibition
N-(pyridin-3-yl)benzamide
-
30% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B6
N-(pyridin-3-yl)pyridine-3-carboxamide
-
8% inhibition of CYP11B2 at 0.5 mM, no inhibition of CYP11B3
N-(pyridin-3-yl)pyridine-4-carboxamide
-
39% inhibition of CYP11B2 at 0.5 mM, 4% inhibition of CYP11B4
norharman
-
beta-carboline, high affinity type II ligand to both cytochromes, progesterone binding to CYP17 competitively inhibited
phosphatidylcholine
-
unsaturated increasing dioleoyl/diphytanoyl phosphatidylcholine
progesterone
-
progesterone acts as a competitive inhibitor for 11beta-hydroxylase and aldosterone synthase, inhibits aldosterone production by wild-type CYP11B1 and chimeric mutant CYP11B1/B2 in HEK-293 cells. The wild-type is more strongly inhibited than the chimera
SKF 525A
-
little inhibition of the purified 11beta-hydroxylase, 18-hydroxylation and aldosterone synthesis of corticosterone are inhibited
spironolactone
-
diuretic and antihypertensive drug, competitive aldosterone antagonist, slight inhibition
18-ethynylprogesterone
-
mechanism-based inhibition; weaker than 18-vinylprogesterone, inhibitor of aldosterone synthesis for both activities, stronger for 18-hydroxylation inhibition
18-ethynylprogesterone
-
mechanism-based inhibition; progesterone analog, time-dependent pseudo-first-order inactivation, concentration dependent
18-ethynylprogesterone
-
suicide-substrate of aldosterone biosythesis, inhibits more strongly the 18-hydroxylation step
18-vinylprogesterone
-
competitive, potent inhibitor of aldosterone synthesis for both activities, 18-hydroxylation more effected, 65% inhibition of corticosterone and 11-deoxy-18-hydroxycorticosterone production by 0.03 mM; mechanism-based inhibition
18-vinylprogesterone
-
mechanism-based inhibition; progesterone analog, with NADPH, time and concentration dependent, irreversible, pseudo-first-order process, covalent binding to and destruction of prosthetic heme group, 5fold more effective than its acetylenic analog 18-ethynylprogesterone
18-vinylprogesterone
-
with 0.001 mM no inhibition detectable, with 0.01 mM 23% decrease in corticosterone production, better suicide-substrate of aldosterone biosythesis than 18-ethynylprogesterone, inhibits more strongly the 18-hydroxylation step
Anti-11beta-hydroxylase IgG
-
polyclonal, raised in rabbits, inhibition of 11-beta/18-hydroxylation and aldosterone synthesis of corticosterone
-
fadrozole
-
isoform-selective inhibitor binding. Fadrozole binds to aldosterone synthase in the R-configuration, using part of the active site cavity pointing toward the egress channel
ketoconazole
-
azole derivative, antimycotic drug, strong dose-dependent inhibition
Metyrapone
-
competitive with substrate, affects strongly 11beta-/18-hydroxylation and 11beta-/19-hydroxylation
Metyrapone
-
diagnostic inhibitor, strong inhibition, 0.02 mM complete inhibition
Metyrapone
-
inhibition of the purified 11beta-hydroxylase, 18-hydroxylation and aldosterone synthesis of corticosterone are inhibited
additional information
-
development and analysis of inhibitory potency of diverse inhibitors by superimposition of active and non-active compounds, modelling based on two pyridyl substituted acenaphthene derivatives, IC50 values of good inhibitors below 100 nM and of weak inhibitors above 300 nM, overview
-
additional information
-
synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis, ligand-protein interactions, docking and molecular dynamics studies using homology-modeled CYP11B2 structure, overview
-
additional information
-
effects of enzyme inhibition of steroid biosynthesis and mineralcorticoid formation, overview
-
additional information
-
a sulfonamide-imidazole scaffold is a potent inhibitor of CYP11B2, the scaffold can achieve high levels of selectivity for CYP11B2 over CYP11B1, overview. Evaluation of a lactam series of derivatives of the R-enantiomer of fadrozole, FAD286, homology modelling, overview
-
additional information
-
synthesis of 23 N-(pyridin-3-yl)benzamides and evaluation for their potential to inhibit steroid-11beta-hydroxylase CYP11B1 and aldosterone synthase CYP11B2, overview. N-(Pyridin-3-yl)benzamides are a highly selective class of CYP11B2 inhibitors in vitro. No or poor inhibition of both isozymes by 3i, 3j, 3l, and 3s
-
additional information
-
three-dimensional modeling of CYP11B2 to model the binding modes of the natural substrate 18-hydroxycorticosterone and the CYP11B2 inhibitor R-fadrozole, overview. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase, overview. Molecular docking in the CYP11B1 and CYP11B2 models
-
additional information
-
development of 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones and structurally related aldosterone synthase inhibitors, molecular modelling, overview. No inhibition of both isozymes by 32 and 15
-
additional information
-
structure homology modelling for inhibitor design, overview
-
additional information
-
estradiol has no effect on aldosterone production by wild-type CYP11B1 and chimeric mutant CYP11B1/B2 in HEK-293 cells
-
additional information
-
conversion of labelled steroid to labelled aldosterone is inhibited by the addition of an excess of the same unlabelled steroid
-
additional information
-
no inhibition with Harman, tetrahydronorharman and tetrahydroharman
-
additional information
-
dexamethasone represses the enzyme in nervous system tissues, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
lipid extract
-
from adrenocortical mitochondria, increase of aldosterone production from corticosterone
-
malate
-
plus NADP+ and in synergism with ascorbate plus NADH increase of aldosterone synthetase activity in zona glomerulosa, no stimulation of 11beta-/18-hydroxylation
NAD(P)H
-
enhance activity of crude extracts that show hydroxylation without any cofactor
phosphatidylcholine
-
saturated acyl chains such as dipalmitoyl/dimyristoyl phosphatidylcholine
additional information
genes amh and cyp11b are both upregulated during juvenile ovary-to-testis transformation
-
additional information
-
genes amh and cyp11b are both upregulated during juvenile ovary-to-testis transformation
-
additional information
-
polychlorinated biphenyl 126 induces CYP11B1 and CYP11B2 expression, 3',4'-dimethoxyflavone synergistically increases the stimulatory effects of PCB126, PCB126 has little effects on the transcription rate of both genes, but protects both RNA transcripts from degradation, mechanism of up-regulation, overview
-
additional information
-
treatment of adult rate ventricular myocytes ACTH and angiotensin II has no stimulatory effect on CYP11B1 and CYP11B2 expression
-
additional information
-
adrenocorticotrophin induces the enzyme in central nervous system tissues, adrenal ectomy does only slightly increase enzyme expression, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.01
11-deoxycorticosterone
-
dipalmitoyl/diphytanoyl-phosphatidylcholine vesicles
0.033
11-deoxycorticosterone
-
dipalmitoyl phosphatidylcholine/diphosphatidyl glycerol vesicles
0.002
adrenal ferredoxin
-
pH 7.4, recombinant enzyme, with 11-deoxycorticosterone as substrate
-
0.0024
adrenal ferredoxin
-
pH 7.4, recombinant enzyme, with 11-deoxycortisol as substrate
-
additional information
additional information
-
kinetic parameters only slightly modified by presence of phospholipids, 0.2% soybean lecithin
-
additional information
additional information
-
lipids such as DLPC required
-
additional information
additional information
-
steady-state kinetics, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.133
11-deoxycorticosterone
-
dipalmitoyl phosphatidylcholine vesicles + diphosphatidyl glycerol
1
adrenal ferredoxin
-
pH 7.4, recombinant enzyme, with 11-deoxycorticosterone as substrate
-
1.48
adrenal ferredoxin
-
pH 7.4, recombinant enzyme, with 11-deoxycortisol as substrate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0000008
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
-
competitive inhibition, pH 7.4
0.0000022
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
-
competitive inhibition, pH 7.4, 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0000024
(1R)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000003
(1S)-2-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-1-phenylethanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000448
1-(1H-inden-2-yl)-1H-imidazole
Homo sapiens
-
CYP11B2 IC50: 448 nM, no inhibition of CYP11B1, recombinant enzymes
0.001
1-(3-cyanobenzyl)-1H-imidazole
Homo sapiens
-
above, inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication; above, inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.001
1-(4-chlorobenzyl)-1H-imidazole
Homo sapiens
-
above, inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication; above, inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000052
2-(4-chlorobenzyl)-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000186
2-benzyl-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000094
2-[(1R)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000617
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000007
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(3-methoxy-2-methylpropyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000013
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-(cyclopropylmethyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000078
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(3-methyloxetan-3-yl)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000008
2-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(propan-2-yloxy)methyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000045
3-(7-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 45 nM, no inhibition of CYP11B1, recombinant enzymes
0.0000114
3-[2-[(1S)-1-(4-chlorophenyl)ethyl]-3,3-dioxido-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazin-4-yl]-2-methylpropan-1-ol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000117
4-(2-methylpropyl)-2-(thiophen-2-ylmethyl)-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000104
4-(2-methylpropyl)-2-[4-(trifluoromethoxy)benzyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000121
4-(2-methylpropyl)-2-[4-(trifluoromethyl)benzyl]-1,2-dihydroimidazo[5,1-d][1,2,5]thiadiazine 3,3-dioxide
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000089 - 0.002077
8-(1H-imidazol-1-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.000001 - 0.000158
8-(5-ethoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000044 - 0.001288
8-(5-fluoropyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000043 - 0.002045
8-(5-hydroxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000006 - 0.000247
8-(5-methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000013 - 0.000058
8-(5-phenylpyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-one
0.0000002 - 0.000013
8-(isoquinolin-4-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000011 - 0.000715
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000012 - 0.000333
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-4-thione
0.000056 - 0.02855
8-(pyrimidin-5-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000036 - 0.000183
8-[5-(2,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000007 - 0.000043
8-[5-(2-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000024 - 0.000128
8-[5-(2-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000023 - 0.000496
8-[5-(3,4-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.000018 - 0.001748
8-[5-(3,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000014 - 0.00049
8-[5-(3-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000012 - 0.000044
8-[5-(3-hydroxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000046 - 0.001374
8-[5-(3-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000009 - 0.00004
8-[5-(4-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000014 - 0.000021
8-[5-(4-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000022 - 0.000103
8-[5-(propan-2-yloxy)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000059 - 0.000141
8-[5-(trifluoromethyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.000016 - 0.002058
8-[5-[3-(trifluoromethoxy)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.000033 - 0.004646
8-[5-[3-(trifluoromethyl)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
0.0000009 - 0.000545
9-(5-methoxypyridin-3-yl)-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
0.0000024 - 0.002296
9-(pyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[ 3,2,1-ij]quinolin-3-one
0.0000002 - 0.000034
9-[6-(isoquinolin-4-yl)pyridin-3-yl]-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
0.0001
additional information
Homo sapiens
-
development and analysis of inhibitory potency of diverse inhibitors by superimposition of active and non-active compounds, modelling based on two pyridyl substituted acenaphthene derivatives, IC50 values of good inhibitors below 100 nM and of weak inhibi
-
0.0000016
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
Homo sapiens
-
competitive inhibition, pH 7.4
0.0000099
(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
Homo sapiens
-
competitive inhibition, pH 7.4, 25°C
0.000334
1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
Homo sapiens
-
CYP11B2 IC50: 334 nM, recombinant enzymes
0.000143
1-(3-bromobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000365
1-(3-bromobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000151
1-(3-chlorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000457
1-(3-chlorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000206
1-(3-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000815
1-(3-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000236
1-(4-aminobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001
1-(4-aminobenzyl)-1H-imidazole
Homo sapiens
-
above, inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000211
1-(4-bromobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000479
1-(4-bromobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000051
1-(4-bromobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000007
1-(4-bromobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000058
1-(4-chlorobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000025
1-(4-chlorobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000368
1-(4-cyanobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000372
1-(4-cyanobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000023
1-(4-cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.00002
1-(4-cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000037
1-(4-cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000057
1-(4-cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000055
1-(4-cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000032
1-(4-cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000052
1-(4-cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000062
1-(4-cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000025
1-(4-cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000027
1-(4-cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000117
1-(4-cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.00013
1-(4-cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000307
1-(4-cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000407
1-(4-cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000007
1-(4-cyanobenzyl)-5-(methyl carboxylate)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000048
1-(4-cyanobenzyl)-5-(methyl carboxylate)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000044
1-(4-cyanobenzyl)-5-(methylene-acetate)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000213
1-(4-cyanobenzyl)-5-(methylene-acetate)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000023
1-(4-cyanobenzyl)-5-bromo-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000073
1-(4-cyanobenzyl)-5-bromo-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000062
1-(4-cyanobenzyl)-5-formyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000478
1-(4-cyanobenzyl)-5-formyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000029
1-(4-cyanobenzyl)-5-hydroxymethyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000285
1-(4-cyanobenzyl)-5-hydroxymethyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000012
1-(4-cyanobenzyl)-5-methyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000141
1-(4-cyanobenzyl)-5-methyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000017
1-(4-cyanobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000028
1-(4-cyanobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.00033
1-(4-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000494
1-(4-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000709
1-(4-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001799
1-(4-fluorobenzyl)-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000011
1-(4-fluorobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000016
1-(4-fluorobenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000011
1-(4-methoxybenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000014
1-(4-methoxybenzyl)-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000411
1-(6-methoxy-3,4-dihydronaphthalen-2-yl)-1H-imidazole
Homo sapiens
-
CYP11B2 IC50: 411 nM, recombinant enzymes
0.000763
1-(6-methoxy-3,4-dihydronaphthalen-2-yl)-1H-imidazole
Homo sapiens
-
CYP11B1 IC50: 763 nM
0.0000048
1-benzyl-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000011
1-benzyl-5-phenyl-1H-imidazole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000161
2,4,5-trifluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000166
2,4,5-trifluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000059
3,4-difluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000535
3,4-difluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000181
3-(1-benzyl-1H-imidazol-5-yl)-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000286
3-(1-benzyl-1H-imidazol-5-yl)-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.00003
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
Homo sapiens
-
CYP11B2 IC50: 30 nM, recombinant enzymes
0.002117
3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
Homo sapiens
-
CYP11B1 IC50: 2117 nM
0.000007
3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
Homo sapiens
-
CYP11B2 IC50: 7 nM, recombinant enzymes
0.001268
3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
Homo sapiens
-
CYP11B1 IC50: 1268 nM
0.00039
3-(1H-imidazol-1-ylmethyl)aniline
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0006
3-(1H-imidazol-1-ylmethyl)aniline
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000007
3-(3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 7 nM, recombinant enzymes
0.000005
3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 5 nM, recombinant enzymes
0.000176
3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 176 nM, recombinant enzymes
0.000013
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
, CYP11B2 IC50: 13 nM, recombinant enzymes
0.001291
3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B1 IC50: 1291 nM
0.000004
3-(6-methoxy-1H-inden-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 4 nM, recombinant enzymes
0.005684
3-(6-methoxy-1H-inden-2-yl)pyridine
Homo sapiens
-
competitive, CYP11B1 IC50: 5684 nM
0.000002
3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 2 nM, recombinant enzymes
0.000578
3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
competitive, CYP11B1 IC50: 578 nM
0.000735
3-[(Z)-2-phenylvinyl]pyridine
Homo sapiens
-
CYP11B2 IC50: 735 nM, no inhibition by the 3-[(E)-2-phenylvinyl]pyridine isomer, recombinant enzymes
0.0000062
3-[1-(4-bromobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000018
3-[1-(4-bromobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000044
3-[1-(4-chlorobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000055
3-[1-(4-chlorobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000013
3-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000048
3-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000016
3-[1-(4-fluorobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000116
3-[1-(4-fluorobenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000012
3-[1-(4-methoxybenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000059
3-[1-(4-methoxybenzyl)-1H-imidazol-5-yl]-1-propanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000005
4-((5-phenyl-1H-imidazol-1-yl)methyl)benzonitrile
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.0000017
4-((5-phenyl-1H-imidazol-1-yl)methyl)benzonitrile
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.002529
4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B1 IC50: 2529 nM
0.002834
4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
Homo sapiens
-
CYP11B2 IC50: 2834 nM, recombinant enzymes
0.000104
4-bromo-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000167
4-bromo-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000102
4-chloro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000065
4-chloro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000075
4-cyano-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000078
4-cyano-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000143
4-fluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000082
4-fluoro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000248
4-nitro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000145
4-nitro-N-(pyridin-3-yl)benzamide
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.0000002
6-(5,8-dihydroisoquinolin-4-yl)-3,4-dihydroquinolin-2(1H)-one
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000033
6-(5,8-dihydroisoquinolin-4-yl)-3,4-dihydroquinolin-2(1H)-one
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000089
8-(1H-imidazol-1-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.002077
8-(1H-imidazol-1-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000001
8-(5-ethoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000158
8-(5-ethoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000044
8-(5-fluoropyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001288
8-(5-fluoropyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000043
8-(5-hydroxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.002045
8-(5-hydroxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000006
8-(5-methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000247
8-(5-methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000013
8-(5-phenylpyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000058
8-(5-phenylpyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000002
8-(isoquinolin-4-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000013
8-(isoquinolin-4-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000011
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000715
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000012
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-4-thione
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000333
8-(pyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-4-thione
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000056
8-(pyrimidin-5-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.02855
8-(pyrimidin-5-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000036
8-[5-(2,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000183
8-[5-(2,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000007
8-[5-(2-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000043
8-[5-(2-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000024
8-[5-(2-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000128
8-[5-(2-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000023
8-[5-(3,4-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000496
8-[5-(3,4-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000018
8-[5-(3,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001748
8-[5-(3,5-difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000014
8-[5-(3-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.00049
8-[5-(3-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000012
8-[5-(3-hydroxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000044
8-[5-(3-hydroxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000046
8-[5-(3-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001374
8-[5-(3-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000009
8-[5-(4-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.00004
8-[5-(4-fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000014
8-[5-(4-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000021
8-[5-(4-methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000022
8-[5-(propan-2-yloxy)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000103
8-[5-(propan-2-yloxy)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000059
8-[5-(trifluoromethyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000141
8-[5-(trifluoromethyl)pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000016
8-[5-[3-(trifluoromethoxy)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.002058
8-[5-[3-(trifluoromethoxy)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000033
8-[5-[3-(trifluoromethyl)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.004646
8-[5-[3-(trifluoromethyl)phenyl]pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000009
9-(5-methoxypyridin-3-yl)-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000545
9-(5-methoxypyridin-3-yl)-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000024
9-(pyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[ 3,2,1-ij]quinolin-3-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.002296
9-(pyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[ 3,2,1-ij]quinolin-3-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000002
9-[6-(isoquinolin-4-yl)pyridin-3-yl]-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000034
9-[6-(isoquinolin-4-yl)pyridin-3-yl]-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-5-one
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000193
methyl 3-(1-benzyl-1H-imidazol-5-yl)-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000326
methyl 3-(1-benzyl-1H-imidazol-5-yl)-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000004
methyl 3-[1-(4-bromobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000057
methyl 3-[1-(4-bromobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000123
methyl 3-[1-(4-chlorobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000177
methyl 3-[1-(4-chlorobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000035
methyl 3-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000031
methyl 3-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.00005
methyl 3-[1-(4-fluorobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000104
methyl 3-[1-(4-fluorobenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000111
methyl 3-[1-(4-methoxybenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000121
methyl 3-[1-(4-methoxybenzyl)-1H-imidazol-5-yl]-propanoate
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.0000146
Metyrapone
Homo sapiens
-
inhibition of CYP11B1, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000072
Metyrapone
Homo sapiens
-
inhibition of CYP11B2, substrate 11-deoxycorticosterone, pH not specified in the publication, temperature not specified in the publication
0.000006
R-fadrozole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000119
R-fadrozole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.00004
S-fadrozole
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.000171
S-fadrozole
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000206
[3-(1H-imidazol-1-ylmethyl)phenyl]methanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001174
[3-(1H-imidazol-1-ylmethyl)phenyl]methanol
Homo sapiens
-
inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
0.000695
[4-(1H-imidazol-1-ylmethyl)phenyl]methanol
Homo sapiens
-
inhibition of CYP11B1, pH not specified in the publication, temperature not specified in the publication
0.001
[4-(1H-imidazol-1-ylmethyl)phenyl]methanol
Homo sapiens
-
above, inhibition of CYP11B2, pH not specified in the publication, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.0000236
-
18-hydroxycorticosterone production, mitochondria from zona fasciculata
0.000119
-
18-hydroxycorticosterone production, mitochondria from zona glomerulosa
0.00206
-
18-hydroxydeoxycorticosterone production, mitochondria from zona glomerulosa
0.00599
-
18-hydroxydeoxycorticosterone production, mitochondria from zona fasciculata
0.00986
-
+/-0.00044, 39.7% inhibition by 0.4 mM metyrapone, adrenal tissue
0.01011
-
+/-0.00126, 38.1% inhibition by 0.4 mM (+)-metyrapol, adrenal tissue
0.01081
-
+/-0.00269, 33.8% inhibition by 0.4 mM (-)-metyrapol, adrenal tissue
additional information
additional information
-
activities of sonicated mitochondria and cholate extract of hydroxylation activities with deoxycotricosterone and 4-androstene-3,17-dione as substrates
additional information
-
dependent on DLPC concentration, with 0.05 mM maximum activity, 2fold increase with addition of 15% glycerol, 0.6 mM GSH, 0.01 mM FAD and 0.01 mM FMN
additional information
-
several activities of 49.5 and 51.5 kDa proteins for multihydroxylation steps
additional information
-
CYP11B2 and CYP11B1 expression analysis in male Wistar rats with heart failure induced by coronary artery ligation and sham-operated controls, in stroke-prone spontaneously hypertensive rats and Wistar Kyoto rats as controls, in cyp1a1Ren-2 transgenic rats and Fischer controls, and in isolated adult Sprague-Dawley ventricular myocytes incubated with 11-deoxycorticosterone, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7.4
7.4
-
assay at
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
20
30
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
2 - 15
-
2fold decrease of activity with increase of temperature, temperatures above 25°C unfavourable
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
isolated mitochondria from human NCI-H295 adrenal cells
-
corresponding to mammalian adrenal gland, P-450(11beta,aldo) and adrenodoxin reductase exist more in outer regions of frogs during the spring and the summer
additional information
-
-
285387, 285389, 285390, 285391, 285393, 285394, 285395, 285396, 285398, 285399, 285400, 285402, 285403, 285404, 285405
-
capsular portion in zona glomerulosa cells, decapsular in zonae fasciculata and reticularis
-
-
-
enzyme expression during sex differentiation and in adult fish at the breeding stage, the enzyme level is higher in the male phase than during testicular differentiation or in the female phase
during development all zebrafish males first develop a juvenile ovary, that later degenerates and transforms into a testis, the enzyme is involved, but not inducing, in gonadal transformation in the zebrafish, but its localization is not related to the position of degenerating oocytes, overview
-
CYP11B shows a highly dimorphic expression pattern throughout gonadogenesis
-
cardiac tissue from several rat models of cardiovascular pathology, low constitutive expression, which seems to be of no physiologic relevance